Physician profile
Michael Lajin
NPI 1467411702
$7,808.98
in general payments reported to CMS, 2019-2025
17 companies · $69.89 in 2025
The $69.89 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,021 · 2020: $119 · 2021: $252 · 2022: $1,002 · 2023: $2,019 · 2024: $326 · 2025: $69.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259 · Travel and Lodging: $1,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,259.13 |
| Travel and Lodging | $1,155.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,955.94 | 2019-2021 | |
| Apollo Endosurgery US INC | $1,356.85 | 2022-2023 | Overstitch Endoscopic Suturing System |
| Abbvie INC. | $645.69 | 2021-2024 | |
| Creo Medical INC. | $537.77 | 2022-2023 | Speedboat |
| Medtronic, INC. | $266.50 | 2023-2025 | Endoflip, Pillcam, Manoscan |
| Pfizer INC. | $212.77 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $166.25 | 2019-2024 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $143.93 | 2021-2024 | Tremfya, Stelara, Simponi Aria |
| Nestle Healthcare Nutrition INC. | $96.21 | 2020-2023 | |
| Braintree Laboratories, INC. | $87.23 | 2021-2024 | Sutab, Suflave |
| Allergan, INC. | $73.40 | 2019-2020 | |
| Vivus LLC | $61.05 | 2022-2023 | Qsymia |
| Micro-Tech Endoscopy USA, INC. | $56.75 | 2024 | Lockado |
| Mauna Kea Technologies, INC. | $48.67 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.31 | 2019-2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $36.27 | 2019-2020 | |
| Conmed Corporation | $18.39 | 2024 | Conmed Biliary |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lajin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.